Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AVIAN INFLUENZA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL AVIAN INFLUENZA DRUG MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL AVIAN INFLUENZA DRUG MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 REGULATORY SCENARIO
6 PREMIUM INSIGHTS
6.1 PESTLE ANALYSIS
6.2 PORTER’S FIVE FORCES
7 INDUSTRY INSIGHTS
8 IMPACT OF COVID-19 PANDEMIC ON THE MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURER/SERVICE PROVIDER
8.5 CONCLUSION
9 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 DRUGS
9.2.1 OSELTAMIVIR (TAMIFLU)
9.2.2 ZANAMIVIR (RELENZA)
9.2.3 RIMANTADINE
9.2.4 OTHERS
9.3 VACCINES
9.3.1 NON-ADJUVANTED
9.3.2 ADJUVANTED
9.3.2.1. SUBVIRION VACCINES
9.3.2.1.1. ALUMINIUM
9.3.2.1.2. AS03
9.3.2.1.3. MF59
9.3.2.1.4. OTHERS
9.3.2.2. WHOLE-VIRION VACCINES
9.3.2.3. VIROSOMAL VACCINE
9.3.3 MODIFIED VACCINIA VIRUS VECTOR VACCINE
9.3.4 LIVE ATTENUATED VACCINE
9.3.5 OTHERS
9.4 OTHERS
10 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY STRAIN TYPE
10.1 OVERVIEW
10.2 H5N1
10.3 H5N6
10.4 H6N1
10.5 H7N4
10.6 H7N9
10.7 H9N2
10.8 H10N8
10.9 OTHERS
11 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 INJECTABLE
12 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY TYPE
12.1 OVERVIEW
12.2 CHICKEN
12.2.1 HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI)
12.2.2 LOW PATHOGENIC AVIAN INFLUENZA (LPAI)
12.3 TURKEY
12.4 GOOSE
12.5 DUCK
12.6 OTHERS
13 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS & CLINICS
13.3 HOME CARE SETTING
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.5 OTHERS
14 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.4 ONLINE PHARMACY
14.5 OTHERS
15 GLOBAL AVIAN INFLUENZA DRUG MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.2 COMPANY SHARE ANALYSIS: EUROPE
15.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.4 MERGERS & ACQUISITIONS
15.5 NEW PRODUCT DEVELOPMENT & APPROVALS
15.6 EXPANSIONS
15.7 REGULATORY CHANGES
15.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL AVIAN INFLUENZA DRUG MARKET, BY REGION
16.1 GLOBAL AVIAN INFLUENZA DRUG MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1.1 NORTH AMERICA
16.1.1.1. U.S.
16.1.1.2. CANADA
16.1.1.3. MEXICO
16.1.2 EUROPE
16.1.2.1. GERMANY
16.1.2.2. FRANCE
16.1.2.3. U.K.
16.1.2.4. ITALY
16.1.2.5. SPAIN
16.1.2.6. RUSSIA
16.1.2.7. TURKEY
16.1.2.8. BELGIUM
16.1.2.9. NETHERLANDS
16.1.2.10. SWITZERLAND
16.1.2.11. REST OF EUROPE
16.1.3 ASIA-PACIFIC
16.1.3.1. JAPAN
16.1.3.2. CHINA
16.1.3.3. SOUTH KOREA
16.1.3.4. INDIA
16.1.3.5. AUSTRALIA
16.1.3.6. SINGAPORE
16.1.3.7. THAILAND
16.1.3.8. MALAYSIA
16.1.3.9. INDONESIA
16.1.3.10. PHILIPPINES
16.1.3.11. REST OF ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.4.1. BRAZIL
16.1.4.2. ARGENTINA
16.1.4.3. REST OF SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.1.5.1. SOUTH AFRICA
16.1.5.2. SAUDI ARABIA
16.1.5.3. UAE
16.1.5.4. EGYPT
16.1.5.5. ISRAEL
16.1.5.6. REST OF MIDDLE EAST AND AFRICA
16.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL AVIAN INFLUENZA DRUG MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL AVIAN INFLUENZA DRUG MARKET, COMPANY PROFILE
18.1 GLAXOSMITHKLINE PLC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPEMENTS
18.2 F. HOFFMANN-LA ROCHE LTD
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPEMENTS
18.3 ALLERGAN
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPEMENTS
18.4 NOVARTIS AG
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPEMENTS
18.5 BAXTER
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPEMENTS
18.6 BIOCRYST PHARMACEUTICALS, INC.
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPEMENTS
18.7 UNM PHARMA INC.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPEMENTS
18.8 CSL LIMITED
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPEMENTS
18.9 EMERGENT BIOSOLUTIONS INC.
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPEMENTS
18.1 NOVAVAX, INC.
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPEMENTS
18.11 MEDIGEN BIOTECHNOLOGY CORP
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPEMENTS
18.12 BIONDVAX PHARMACEUTICALS LTD.
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPEMENTS
18.13 INOVIO PHARMACEUTICALS
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPEMENTS
18.14 VAXART, INC.
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPEMENTS
18.15 JOHNSON & JOHNSON SERVICES, INC.
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPEMENTS
18.16 SINOVAC
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPEMENTS
18.17 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPEMENTS
18.18 CEVA
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPEMENTS
18.19 ZOETIS
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPEMENTS
18.2 QIANYUANHAO BIOLOGICAL CO., LTD.
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
19 RELATED REPORTS
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
